Kailera Therapeutics raised $719 million in its IPO, the largest in biotech history. The deal was priced at the top end of its marketed range, upsized, and closed up 62.5% on its first trading day. The company is now valued at approximately $3 billion.
Kailera’s IPO highlights the strong demand for next-generation treatments for obesity. It is also the first biotech IPO post the start of the war in Iran. The six IPOs in January and February suggested a recovery after the long bear market. Kailera reaffirms the trend is very much intact.
The deal comes as investor excitement is focused on a few specific areas, with weight-loss therapies among those at the center. Morgan Stanley projects that the global obesity treatment market will reach $150 billion in peak sales by 2035.
Kailera's Position in the GLP-1 Market
Kailera is the leader in a cohort of biotechs challenging pharma companies’ position in the GLP-1 market.
The company was co-created by Bain, RTW Investments, Atlas, and Hengrui Pharmaceuticals, and is led by CEO Ron Renaud. Kailera acquired ex-China rights from Hengrui to create a pipeline of GLP-1–based therapies.
Its lead program, ribupatide (KAI-9531), is a once-weekly injectable GLP-1/GIP dual agonist currently in global Phase 3 trials. In Phase 2 studies, the drug delivered weight loss of over 20% at 36 weeks, competitive with Phase 2 data from leading next-gen candidates from Eli Lilly and Viking Therapeutics. The company is also developing two orals: an oral version of ribupatide and KAI-7535, a small-molecule GLP-1 agonist, are in Phase 2. Ron has stated that Kailera has “the most advanced and diverse obesity portfolio outside of Big Pharma.”
These programs reflect where the field is heading. First-generation GLP-1 therapies have demonstrated strong weight loss and cardiovascular benefits. The focus now is on improving on the various attributes of these medicines:
Further increasing weight loss
Reducing side effects, most importantly nausea and vomiting
More convenient dosing
Expanding access with small molecules
Novel and combination mechanisms
Muscle-sparing, targeted fat loss
Kailera is part of a cohort of emerging biotechs seeking to challenge Eli Lilly and Novo Nordisk. Some pharmas are turning to these start-ups as a means to enter as well. Last year, Pfizer and Novo waged a bidding war for Metsera. Pfizer ultimately paid $10 billion to access Metsera’s portfolio of long-acting injectable GLP-1s and amylin analogs.
The Increase in Recent Biotech IPOs
Prior to Kailera’s April IPO, six other biotechs made it out in January and February, compared to eight in total in 2025.
Aktis Oncology raised $318 million
Generate: Biomedicines $400 million
Veradermics $256 million
SpyGlass Pharma $150 million
Agomab Therapeutics $200 million
Eikon Therapeutics $381 million
Agomab and Generate focus on immunology; Aktis and Eikon on cancer, two other therapeutic areas with booming innovation.
Companies that are able to raise capital in current markets share a few characteristics:
Clinically validated assets or targets
Pursuing large markets or significant unmet needs
A clear development path
These deals show that capital is available but more concentrated in asset focused companies rather than platforms or discovery stage science.
Will the IPO Market Momentum Continue?
The question post Kailera’s IPO is whether momentum can continue. Our view at RTW is that the path of least resistance is a continued recovery. While, of course, a re-escalation in Iran or other economic shocks are key variables, the house view is the IPO market is on a path to normalization.
Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results.
